Tag: Ocugen

Ocugen is betting that a single therapeutic can rewrite the rules for treating inherited retinal diseases. Its lead candidate, OCU400, ...

Ocugen’s stock has been on a rollercoaster, sliding 25% over the past month to trade at €1.18, but the company ...

Ocugen has parted ways with its chief medical officer just as the biotech enters a pivotal stretch for its lead ...

Ocugen is making quiet but meaningful progress across its pipeline of gene therapy programmes, yet the stock tells a more ...

Ocugen has pulled off a financing manoeuvre that slashes its interest burden in half, using a $130 million convertible bond ...

Ocugen has closed a $115 million convertible note offering that buys the biotech group more than two years of operating ...

On paper, Ocugen has everything a small-cap biotech investor could want: seven buy ratings, zero holds or sells, and a ...

Ocugen is racing against its own balance sheet. The biotech has mapped out a clinical calendar for 2026 that packs ...

A critical legal hearing scheduled for May 6 in Delaware could resolve a major uncertainty hanging over gene therapy developer ...

The biotech firm Ocugen is undergoing a significant strategic evolution, transitioning from a research-focused entity into a late-stage clinical developer ...